Rockefeller University Jul 4 2025 The COVID pandemic illustrated how urgently we need antiviral medications capable of treating coronavirus infections. To aid this effort, researchers quickly homed in on part of SARS-Cov-2's molecular structure known as the NiRAN domain-an enzyme region essential to viral replication that's common to many coronaviruses. A drug targeting the NiRAN domain would likely work broadly to shut down a range of these pathogens, potentially treating known diseases like

Tag-uri: Coronavirus